Pharmaceuticals & Biotech U.S. Community

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more

Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.Read more

TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57 Terns Pharmaceuticals (TERN) is fundamentally undervalued based on the clinical profile of its lead oncology asset, TERN-701. The latest data establish a clear trajectory for market leadership in Chronic Myeloid Leukemia (CML), justifying an intrinsic valuation target of 98.57 per share.Read more

Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Read more

It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

Hello Simply Wallstreet I have some DD on a small cap company I want to share. Firstly I want you all to be aware of the risks associated with small caps.Read more

https://www.marketviews.com/trending-etf/?utm_source=Backfill&utm_medium=native&utm_term=MarketWatch&utm_campaign=ROWhttps://www.tradingview.com CEO of Bitcoin and Ai Name: Ralf P. Carreon Location: Purok 13,Tenago Poblacion Kapatagan Lanao Del Norte 9214, Philippines My Birthday: June 28, 1993 My email: ralfcarreon0@gmail.com My # : 09853162851Read more